Eletriptan indications and usage: Difference between revisions

Jump to navigation Jump to search
(Created page with "__NOTOC__ {{Eletriptan}} {{CMG}} == <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = RELPAX (ELETRIPTAN HYDROBROMIDE) TABLET, FILM COATED [ROERI...")
 
mNo edit summary
 
Line 3: Line 3:
{{CMG}}
{{CMG}}


==
==Indications and Usage==


RELPAX is indicated for the acute treatment of migraine with or without aura in adults.


====Limitations of Use====


<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = RELPAX (ELETRIPTAN HYDROBROMIDE) TABLET, FILM COATED [ROERIG] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=85745375-fcb6-4edc-b6db-a77b4a5f3e8c | publisher =  | date =  | accessdate = }}</ref>
Use only if a clear diagnosis of migraine has been established. If a patient has no response to the first migraine attack treated with RELPAX, reconsider the diagnosis of migraine before RELPAX is administered to treat any subsequent attacks.
 
RELPAX is not intended for the prevention of migraine attacks.
 
Safety and effectiveness of RELPAX have not been established for cluster headache.<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = RELPAX (ELETRIPTAN HYDROBROMIDE) TABLET, FILM COATED [ROERIG] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=85745375-fcb6-4edc-b6db-a77b4a5f3e8c | publisher =  | date =  | accessdate = }}</ref>


==References==
==References==

Latest revision as of 07:46, 10 February 2014

Eletriptan
RELPAX® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials on Eletriptan
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Indications and Usage

RELPAX is indicated for the acute treatment of migraine with or without aura in adults.

Limitations of Use

Use only if a clear diagnosis of migraine has been established. If a patient has no response to the first migraine attack treated with RELPAX, reconsider the diagnosis of migraine before RELPAX is administered to treat any subsequent attacks.

RELPAX is not intended for the prevention of migraine attacks.

Safety and effectiveness of RELPAX have not been established for cluster headache.[1]

References

  1. "RELPAX (ELETRIPTAN HYDROBROMIDE) TABLET, FILM COATED [ROERIG]".

Adapted from the FDA Package Insert.